5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
Zacks·3d ago
More News
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros
StoneCo, General Motors, Enersys, Deutsche, Keros have been highlighted in this Screen of The Week article.
Zacks·3d ago
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.
Zacks·4d ago
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS
TFG Asset Management GP Ltd reduced its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 30.1% during the second quarter, according to the company in its most recent Form 13F filing...
MarketBeat·6d ago
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·7d ago
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
Zacks·7d ago
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 67.2% during the second quarter...
MarketBeat·7d ago
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
Federated Hermes Inc. lessened its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 46.6% during the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·7d ago
Keros Therapeutics (NASDAQ:KROS) Trading Up 12% - Here's Why
Keros Therapeutics (NASDAQ:KROS) Shares Up 12% - Here's Why...
MarketBeat·14d ago
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00
Bank of America raised their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a "neutral" rating in a report on Friday...